Sage Journals: Discover world-class research

Abstract

Objective

We conducted a systematic review and meta-analysis aiming to assess the efficacy and safety of Nivolumab treatment in patients with newly diagnosed and recurrent glioblastoma multiforme (GBM).

Data sources

Our study followed the guidelines outlined in the preferred reporting items for systematic reviews and meta-analyses (PRISMA) recommendations. The protocol for this review can be found in the International Prospective Register of Systematic Reviews Database (CRD42022340071). We performed searches on the Medline, PubMed, Embase, Scopus, and Web of Science databases.

Data summary

A total of 545 studies were identified through our comprehensive search across the five databases (PubMed: 78, Embase: 82, Medline: 173, Scopus: 138, Web of Science: 74). After conducting a thorough analysis, our meta-analysis indicated that treatment with Nivolumab led to improved overall survival (OS) outcomes in newly diagnosed glioblastoma patients, as evidenced by a prolonged median OS based on trial data. However, there was no significant beneficial effect observed in terms of median progression-free survival (PFS), as well as OS at 6, 12, and 24 months. Furthermore, our results demonstrated no efficacy of Nivolumab in the treatment of recurrent GBM patients.

Conclusions

In conclusion, Nivolumab demonstrated promising results that warrant further investigation for its use in newly diagnosed glioblastoma patients. However, its effectiveness was not observed in the context of recurrent GBM.

Keywords

Glioblastoma Nivolumab cancer inhibitors checkpoints

Get full access to this article

View all access options for this article.

References

Ostrom

Gittleman

Truitt

, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. J Neurooncol 2018; 20: iv1–iv86.

Louis

Perry

Reifenberger

, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol (Berl) 2016: 803–820.

Davis

. Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs 2016; 20: S2–S8.

Friedman

Prados

Wen

, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733–4740.

Dolecek

Propp

Stroup

, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol 2012; 14: v1–v49.

Wei

, et al. Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance. Pharmacol Res 2021; 171: 105780.

Sharma

Allison

. The future of immune checkpoint therapy. Science 2015; 348: 56–61.

Reardon

Gokhale

Klein

, et al. Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol Res 2016; 4: 124–135.

Lim

Xia

Bettegowda

, et al. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol 2018; 15: 422–442.

10.

Ledford

Else

Warren

. Cancer immunologists scoop medicine Nobel prize. Nature 2018; 562: 20–21.

11.

Rotte

D’Orazi

Bhandaru

. Nobel committee honors tumor immunologists. J Exp Clin Cancer Res 2018; 37: 262.

12.

Shen

Chen

. Immune checkpoint blockade therapy: the 2014 tang prize in biopharmaceutical science. Biom J 2015; 38: 5.

13.

Moher

Liberati

Tetzlaff

, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: 1–14.

14.

Min

Hodi

Kaiser

. Corticosteroids and immune checkpoint blockade. Aging (Albany NY) 2015; 7: 521–522.

15.

Pitter

Tamagno

Alikhanyan

, et al. Corticosteroids compromise survival in glioblastoma. Brain 2016; 139: 1458–1471.

16.

Chongsathidkiet

Jackson

Koyama

, et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med 2018; 24: 1459–1468.

17.

Wong

Lok

Gautam

, et al. Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma. Br J Cancer 2015; 113: 232–241.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB

0.54 MB